No­vo Nordisk ax­es 2 more obe­si­ty drugs as lead­ing drugs 'raise the bar'; Div­ing deep­er in­to R&D, CSL adds sup­port for biotech in­cu­ba­tor

No­vo Nordisk is once again whit­tling away at its pipeline of obe­si­ty drugs.

In it lat­est quar­ter­ly up­date the phar­ma com­pa­ny not­ed:

In June 2020, No­vo Nordisk ter­mi­nat­ed the GG-co-ag­o­nist and tri-ag­o­nist phase 1 de­vel­op­ment projects. Re­cent da­ta from the phase 3 de­vel­op­ment pro­gramme, STEP, for semaglu­tide in obe­si­ty and the clin­i­cal tri­als with AM833 as monother­a­py and in com­bi­na­tion with semaglu­tide have raised the in­no­va­tion bar in Obe­si­ty care, which has led to a pri­ori­ti­sa­tion with­in the Obe­si­ty care de­vel­op­ment port­fo­lio and ter­mi­na­tion of the projects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER